RxDoctor Payments Data

Erica Kaufman West, MD

Infectious Disease · Dyer, INNPI 1619075785

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $38,436 of the $48,402 with a category attached, or 79.4%. 19 manufacturers reported payments, led by Gilead at 54.3% of the total. Reporting peaked in 2019 at $24,566 and has fallen 99.8% since, to $39 in 2025. Among infectious disease clinicians in IN with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$48,402in general payments, 2019–2025

Across 160 payments — averaging $302.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Gilead$26K
  • AbbVie$21K
  • Merck$300
  • Viiv Healthcare Company$216
  • Janssen Products, LP$208
  • Astellas Pharma US Inc$205
  • plus $663 from 13 others
$102,633in research payments, 2019–2025

Across 7 payments — averaging $14,662 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Eli Lilly$103K

What the payments were for

  • Consulting fees$2,7256%
  • Speaking & faculty fees$38,43679%
  • Travel & lodging$4,2189%
  • Food & beverage$2,7576%
  • Education$2661%

General payments by program year

19
20
21
22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$48,402 in reported general payments places this provider in the 95th percentile of 152 infectious disease providers in Indiana.

See all infectious disease providers in Indiana

Medicare billing

Part B allowed, 2024
$15,871
Medicare patients
67
Services billed
307

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TriumeqAbacavir/Dolutegravir/Lamivudi22$79,146
SymtuzaDarunavir/Cob/Emtri/Tenof Alaf14$64,854
BiktarvyBictegrav/Emtricit/Tenofov Ala13$50,924
TivicayDolutegravir Sodium11$46,684
GenvoyaElviteg/Cob/Emtri/Tenof Alafen11$43,763
DelstrigoDoravirine/Lamivu/Tenofov Diso16$42,878
PifeltroDoravirine20$34,007
PrezcobixDarunavir/Cobicistat11$25,438
VemlidyTenofovir Alafenamide13$17,649
GlyxambiEmpagliflozin/Linagliptin11$6,868
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen13$60
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim13$44

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Viiv Healthcare CompanyTriumeq, Tivicay$216$125,83033 claims
GileadBiktarvy, Genvoya, Vemlidy$26,305$112,33637 claims
MerckDelstrigo, Pifeltro$300$76,88536 claims
Janssen Products, LPSymtuza$208$64,85414 claims
Johnson & JohnsonPrezcobix$79$25,43811 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 152 infectious disease providers in Indiana.

Other infectious disease in Dyer

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →